USPTO serial 97849603
ASTER INSIGHTS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 25, 2025
- Examiner
- WEIGLE, KATHERINE CONNOLLY
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ASTER INSIGHTS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen K. Won
Karen K. Won Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo P.C.One Financial CenterBoston, MA 02111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Providing an electronic database for the collection and storage of clinical and molecular data derived from a patient, namely, an electronic database featuring medical and scientific research information in the field of human clinical and molecular data analysis for aiding medical diagnostics, discovery and development and prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases; medical and scientific research data analysis and bioinformatics consulting services relating thereto, namely, computer software consulting, providing online non-downloadable computer software platforms for analyzing medical and scientific research data, and scientific research data analytics consulting in connection with an electronic database for the collection and storage of medical and scientific research information in the fields of clinical and molecular data accumulated for aiding medical diagnostic, discovery and development and prognostics and evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases; providing an Internet-accessible website portal featuring medical records for use by physicians, patients and researchers for the storage and accessibility of electronic medical research data in the field of human clinical and molecular data and analysis for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness; providing consulting services relating thereto for the aforementioned services | ACTIVE | Apr 14, 2023 |
| 044 | Providing an electronic database for the collection and storage of clinical and molecular data derived from a patient, namely, an electronic database featuring medical information in the field of human clinical and molecular data analysis for aiding medical diagnostics, discovery and development and prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases; Health care services, namely, providing a database in the field of cancer and other disease medical information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Providing a database in the field of human clinical and molecular data accumulation and analysis for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness, namely, providing medical information data regarding tumor-specific molecular signatures, providing objective medical information data on the effectiveness of a drug and/or diagnostic test, and providing evidence-based treatment protocols by effectively comparing standard treatment therapies with clinical outcomes; collection and analysis of data services in the field of human clinical and molecular data for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases, namely, medical services in the nature of matching particular patients to a particular drug, treatment, therapy or clinical trial by the specific molecular signature of the patient; providing an Internet-accessible website portal featuring medical records for use by physicians, patients and researchers for the storage and accessibility of electronic medical information data in the field of human clinical and molecular data and analysis for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness; providing consulting services relating thereto for the aforementioned services. | ACTIVE | Apr 14, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 11, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 11, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 11, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 11, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 11, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 25, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 25, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 28, 2025 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 28, 2025 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Feb 22, 2025 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Feb 22, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 11, 2024 | IUAF | USE AMENDMENT FILED | — |
| Dec 11, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jun 18, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 23, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 23, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 3, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 3, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 3, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 21, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 21, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 21, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 21, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 21, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 28, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 28, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 19, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 19, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 19, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 18, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 15, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 12, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 24, 2023 | NWAP | NEW APPLICATION ENTERED | — |